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Pharmaceutical tabletsAbstract A simple and selective HPLC-DAD stability indicating method was developed for the
simultaneous determination of the three antihypertensive drugs amlodipine besylate (AML), valsar-
tan (VAL) and hydrochlorothiazide (HCT) in their combined formulation. Effective chromato-
graphic separation was achieved using Zorbax SB-C8 column (4.6 · 250 mm, 5 lm ps) with
gradient elution of the mobile phase composed of 0.025 M phosphoric acid and acetonitrile at a
ﬂow rate of 1 mL/min. The multiple wavelength detector was set at 238 nm for measurement of
AML and 225 nm for both VAL and HCT. Quantiﬁcation was based on measuring the peak areas.
The three compounds were resolved with retention times of 4.9, 6.4 and 8.3 min for HCT, AML and
VAL respectively. Analytical performance of the proposed HPLC procedure was statistically vali-
dated with respect to system suitability, linearity, ranges, precision, accuracy, speciﬁcity, robustness,
detection and quantiﬁcation limits. The linearity ranges were 5–200, 5–200 and 10–200 lg/mL for
AML, VAL and HCT respectively with correlation coefﬁcients >0.9993. The three drugs were sub-
jected to stress conditions of acidic and alkaline hydrolysis, oxidation, photolysis and thermal deg-
radation. The proposed method proved to be stability-indicating by resolution of the analytes from
their forced-degradation products. The validated HPLC method was applied to the analysis of the
cited antihypertensive drugs in their combined pharmaceutical tablets (Exforge HCT). The pro-
posed method made use of DAD as a tool for peak identity and purity conﬁrmation.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Amlodipine besylate (AML) is a dihydropyridine calcium
channel blocker used in the treatment of hypertension and an-
gina pectoris (Sweetman, 2009). Valsartan (VAL) is an
S1382 R.A. Shaalan et al.angiotensin II receptor antagonist used in the management of
hypertension, to reduce cardiovascular mortality in myocar-
dial infarction patients and in the management of heart failure
(Sweetman, 2009). Hydrochlorothiazide (HCT) is a moder-
ately potent diuretic used in the treatment of hypertension
either alone or with other antihypertensives. It is also used
to treat edema associated with heart failure and with renal
and hepatic disorders (Sweetman, 2009). Fig. 1 shows the
chemical structures of the three compounds. In 2009, the US
Food and Drug Administration (FDA) and the European
Medicines Agency approved a triple ﬁxed-dose combination
of AML, VAL and HCT. It was found that the use of this tri-
ple combination was generally more effective in reducing
blood pressure and providing overall blood pressure control
than the dual combination therapies regardless of age, race,
gender, ethnicity, or hypertension severity (Calhoun et al.,
2009 and Chrysant, 2011).
The simultaneous determination of AML and VAL in their
binary combination was addressed in several analytical re-
ports. These reports proposed spectrophotometric (Gupta
et al., 2010 and Kul et al., 2010), spectroﬂuorimetric (Shaalan
and Belal, 2010), TLC (Dhaneshwar et al., 2009 and Ramadan
et al., 2010) and several HPLC methods with UV detection
(Kul et al., 2010, Patel et al., 2009 and Ramadan et al.,
2010). In addition, both drugs were determined in human plas-
ma using HPLC with ﬂuorescence detection (Khalil et al.,
2011) and capillary electrophoresis (Alnajjar, 2011). On the
other hand, the simultaneous determination of VAL and
HCT was carried out using various spectrophotometric meth-
ods (Deshpande et al., 2012, Dinc et al., 2004, Erk, 2002,
Lakshmi and Lakshmi, 2011 and Satana et al., 2001), HPLC
(Ahmed et al., 2011, Ivanovic et al., 2007 and Satana et al.,
2001), HPTLC (Kadam and Bari, 2007), and capillary electro-
phoresis (Hillaert and Van den Bossche, 2003). Additionally,
HPLC-MS–MS was applied for the quantiﬁcation of both
drugs in human plasma (Li et al., 2007, Liu et al., 2008 and
Shah et al., 2009).
Few reports can be found in the scientiﬁc literature for
the simultaneous determination of AML, VAL and HCT.H
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Figure 1 Chemical structures of amlodipine besylate (AMThese reports presented spectrophotometric (Anandakumar
and Jayamariappan, 2011, and Nikam et al., 2010) HPTLC
(Galande et al., 2011 and Varghese and Ravi, 2011) and
some HPLC methods (Anandakumar et al., 2012, Galande
et al., 2011, Shaalan and Belal, 2012, Varghese and Ravi,
2011, Vignaduzzo et al., 2011). Speciﬁcity was tested in
only one previous report (Shaalan and Belal, 2012) by sep-
aration of the three analytes from several other pharmaceu-
tical compounds, however, none of these previous reports
was selective enough to resolve the three drugs from their
potential impurities and forced-degradation products, and
consequently, none of these procedures can be considered
stability-indicating.
This work describes development, validation, and applica-
tion of a new simple, selective and reliable HPLC-DAD meth-
od for the analysis of AML-VAL-HCT drug combination. The
method was validated for its speciﬁcity and stability-indicating
properties by resolution of the cited drugs from their forced
hydrolytic, oxidative, photolytic and dry heat degradation
products.
2. Experimental
2.1. Instrumentation
The HPLC-DAD system consisted of Agilent 1200 series
(Agilent Technologies, Santa Clara, CA, USA) (quaternary
pump, vacuum degasser and diode array and multiple wave-
length detector G1315 C/D and G1365 C/D) connected to a
computer loaded with Agilent ChemStation Software. A
Rheodyne manual injector with 20 lL loop was used. The
column used was Zorbax SB-C8 (4.6 · 250 mm, 5 lm particle
size) (Agilent).
2.2. Materials
Amlodipine besylate (AML) was kindly supplied by Pﬁzer
Egypt S.A.E., Cairo, Egypt, valsartan (VAL) was kindlyN COOH
CH3H3C
H3C
N
NN
HN
O
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N
H
NH
S
OO
HCT
L), valsartan (VAL) and hydrochlorothiazide (HCT).
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chlorothiazide (HCT) was kindly donated by Pharco Pharma-
ceuticals Co., Alexandria, Egypt. HPLC-grade acetonitrile
(Scharlau Chemie S.A., Sentmenat, Spain), HPLC-grade
methanol (Sigma–Aldrich Chemie GmbH, Buchs, Switzer-
land), analytical grade of ortho-phosphoric acid, hydrochloric
acid, sodium hydroxide, 50% hydrogen peroxide and high pur-
ity distilled water were used. Pharmaceutical preparation con-
taining the three drugs is Exforge HCT tablets labeled to
contain 10 mg AML, 320 mg VAL and 25 mg HCT (Novartis
Pharma, Switzerland) was purchased from the local market.
2.3. General procedure
2.3.1. Chromatographic conditions
A mobile phase system consisting of 0.025 M phosphoric acid
and acetonitrile was used. The separation was achieved with
the linear gradient program shown in Table 1. The ﬂow rate
was 1.0 mL/min. The injection volume was 20 lL. The eluant
was monitored by the diode array detector from 190 to
400 nm, and chromatograms were extracted at the wavelengths
of 225 and 238 nm. All determinations were performed at 25 C.
2.3.2. Standard solutions
AML (1000 lg/mL), VAL (2000 lg/mL) and HCT (1000 lg/
mL) stock solutions were prepared in HPLC-grade methanol.
The working solutions were prepared by dilution of aliquots of
the stock solutions with distilled water to reach the concentra-
tion ranges 5–200, 5–200 and 10–200 lg/mL for AML, VAL
and HCT, respectively. Triplicate injections were made for
each concentration and chromatographed under the previously
described LC conditions. The peak areas were plotted against
the corresponding concentrations to construct the calibration
graphs.
2.4. Assay of commercial tablets
Ten Exforge HCT tablets were weighed and ﬁnely powdered.
HPLC-grade methanol (30 mL) was added to a quantity of the
powdered tablets equivalent to 5 mg AML, 160 mg VAL and
12.5 mg HCT, the solution was stirred for 10 min then ﬁltered
into a 50-mL calibrated ﬂask. The residue was washed with
2 · 5 mL methanol and washings were added to the ﬁltrate
and diluted to ﬁnal volume with methanol. Aliquots of the tab-
let solution were diluted with distilled water to obtain ﬁnal
concentrations within the speciﬁed ranges then treated as un-
der General Procedure and recovered concentrations were cal-
culated from the corresponding calibration graphs. For
standard addition assay, sample solutions were spiked with ali-
quots of standard solutions of the three compounds to obtain
total concentrations within the previously speciﬁed ranges thenTable 1 Gradient program used in the study.
Time (min) 0.025 M H3PO4% Acetonitrile% Flow (mL/min)
0 75 25 1
4 50 50 1
5 25 75 1
15 25 75 1treated as under General Procedure. Recovered concentrations
were calculated by comparing the analyte response with the
increment response attained after addition of the standard.
2.5. Forced degradation and stability-indicating study
Forced degradation studies were carried out on AML, VAL
and HCT standards according to the following conditions:
(a) Acidic and basic conditions: AML, VAL and HCT solu-
tions were treated with 1 mL of 1 M HCl or 1 M NaOH.
The solutions were placed in a water bath at 90 C for
1 h, except for AML solution where the time was
reduced for only 10 min at 90 C in HCl and at 60 C
in NaOH. In case of VAL the time for basic degradation
was extended for 2 h at 90 C. After the speciﬁed time,
all solutions were neutralized by adjusting the pH to
7.0 and then diluted to volume with distilled water to
obtain a ﬁnal concentration of 20 lg/mL each.
(b) Oxidation with H2O2: AML, VAL and HCT solutions
were treated with 0.5 mL of hydrogen peroxide 5%.
The solutions were placed in a water bath at 80 C for
1 h, except for AML the time was extended for 2 h. After
the speciﬁed time intervals, the solutions were diluted to
volume with distilled water to obtain a ﬁnal concentra-
tion of 20 lg/mL each.
(c) Photolytic degradation: An amount of each drug pow-
der (100 mg) was subjected to UV irradiation at
254 nm for 60 h. After the speciﬁed time, each powder
was dissolved in methanol, and aliquots of these metha-
nolic stocks were diluted to volume with distilled water
to obtain a ﬁnal concentration of 20 lg/mL each.
(d) Dry heat degradation: An amount of each drug powder
(100 mg) was kept in an oven at 90 C for 18 h. After the
speciﬁed time, each powder was dissolved in methanol,
and aliquots of these methanolic stocks were diluted to
volume with distilled water to obtain a ﬁnal concentra-
tion of 20 lg/mL each.
After the previous treatments, solutions were ﬁltered with a
0.45 lm ﬁltration disk prior to injection to the column.
3. Results and discussion
With the development of International Conference on Harmo-
nization (ICH) guidelines, the requirement of establishment of
a stability-indicating assay method (SIAM) has become more
clearly mandatory. The guidelines require conducting of forced
decomposition studies under a variety of conditions, like pH,
light, oxidation, dry heat and others followed by separation
of drug from degradation products (ICH, 1993). Because of
the requirement of separation of multiple components during
the analysis of stability samples, HPLC has gained popularity
in stability studies due to its high-resolution capacity, sensitiv-
ity and speciﬁcity.
The work proposed in this paper was directed toward the
study of the chromatographic behavior of the products of
stress degradation of the three antihypertensives AML, VAL
and HCT; as well as the simultaneous determination of the
three drugs in their combined formulation. The fact that up till
now the stability indicating analysis of this drug combination
has not been reported in the literature has encouraged us to
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Figure 2 HPLC chromatograms of 20 lL injection of a mixture containing 20 lg/mL AML, 160 lg/mL VAL and 25 lg/mL HCT at
225 nm (A) and 238 nm (B).
Table 2 System suitability parameters for the HPLC-DAD determination of AML-VAL-HCT mixture.
Parameter HCT AML VAL
tR ± SD (min) 4.89 ± 0.058 6.42 ± 0.018 8.29 ± 0.017
Capacity factor (k0) 1.39 2.13 3.04
Theoretical plates (N) 19884 36497 71028
Selectivity (a) 1.53 1.43
Resolution (Rs) 11.13 13.87
S1384 R.A. Shaalan et al.develop an HPLC- DAD stability indicating assay where the
decomposition products were resolved from the intact drugs.
Forced-degradation studies should be considered during
development of chromatographic procedures particularly
when degraded products are unknown or not available (Klick
et al., 2005). Hence, forced-degradation experiments were car-
ried out on AML, VAL and HCT in order to produce the pos-
sible relevant degradants and test their chromatographic
behavior using the developed HPLC method. Hydrolytic
(using both strong acidic and basic media) and oxidativedegradation studies were conducted either at room tempera-
ture or with the aid of heating. Moreover the dry heat and
photolytic stress conditions were applied.
3.1. Optimization of chromatographic conditions
Reviewing the literature revealed that only few papers de-
scribed the simultaneous determination of AML, VAL, and
HCT, one of these reports is a gradient liquid chromato-
graphic method coupled with diode array detection Shaalan
Validated stability-indicating HPLC-DAD method of analysis for the antihypertensive triple mixture S1385and Belal, 2012 for the analysis of this ternary mixture in
their combined pharmaceutical preparation. The mobile
phase system optimized in the aforementioned paper con-
sisted of (A) 0.025 M phosphoric acid and (B) acetonitrile
with a linear gradient program and it was taken as an early
initiative in our work. Several gradient programs using phos-
phoric acid and acetonitrile were tried and further optimized,
concerning the ratio of acetonitrile to the aqueous phase in
the system as well as the time of gradient program, so as
to fulﬁll the requirement of resolving the three drugs from
each other and from their stress degradation products. Aceto-
nitrile in high concentration (>65%, v/v) was an important
factor that led to the elution of VAL in a reasonable reten-
tion time with acceptable peak asymmetry. On the other
hand, using the mobile phase with a high proportion of ace-
tonitrile in the gradient mode resulted in a complication for
the quickly eluting HCT peak. To overcome this conﬂict
and to ensure complete resolution of the active ingredients
from other extra forced degradation peaks, the best compro-
mise among adequate resolution, reasonable retention times,
and tolerable peak asymmetry was achieved using a gradient
system starting with 25% (v/v) acetonitrile ramped up line-
arly to 50% in 4 min, at 5 min acetonitrile was further
ramped to 75% and then maintained at this percentage after-
ward for 15 min (Table 1). The effect of ﬂow rate was stud-
ied, and 1.0 mL/min was found optimum regarding run time,
peak asymmetry, and column pressure and was kept constant
throughout the gradient program. The multiple wavelength
detector offers the advantage of measuring each analyte at
its maximum absorption wavelength, thus improving sensitiv-
ity; AML was measured at 238 nm while HCT and VAL were
measured at 225 nm. In addition, diode array detection en-
hances the power of HPLC and is an elegant option for
assessing method speciﬁcity by comparison of recorded spec-
tra during peak elution. Quantiﬁcation was achieved using
diode array detection based on peak area measurement.Table 3 Summary of degradation studies of AML-VAL-HCT usin
Analyte Degradation conditions Degradatio
1- Acidic degradation
AML 90 C for 10 min 30
VAL 90 C for 1 h 50
HCT 90 C for 1 h 75
2- Basic degradation
AML 60 C for 10 min 35
VAL 90 C for 2 h 13
HCT 90 C for 1 h 30
3- Oxidative degradation
AML 80 C for 2 h 25
VAL 80 C for 1 h 40
HCT 80 C for 1 h 30
4- Photo-degradation
AML UV at 254 nm for 60 h –
VAL UV at 254 nm for 60 h 6
HCT UV at 254 nm for 60 h 13
5- Thermal degradation (dry heat)
AML 90 C for 18 h –
VAL 90 C for 18 h 5
HCT 90 C for 18 h –The previously described gradient program was established
with a view to develop a stability indicating assay method
where AML, VAL and HCT were resolved with symmetrical
peaks, Fig. 2 shows a typical chromatogram for the separation
of the three drugs. Moreover, the chromatographic conditions
described above gave good separation between each of the
three drugs and their stress degradation products. Resolution
as well as other system suitability parameters was calculated
and they were found acceptable (Table 2).
3.2. Stability indicating aspects
Forced-degradation experiments were carried out on each of
the three drugs in this combination in order to produce the
possible relevant degradants and test their chromatographic
behavior using the developed method. Hydrolytic (using both
strong acidic and basic media), oxidative degradation, dry heat
and photolytic degradation studies were conducted under dif-
ferent conditions of time and temperature (Table 3). HCT is
susceptible to degradation in both acidic and basic media. In
strong acidic medium, degradation of HCT was noticed from
the decrease of its peak area which reached 10% of the ex-
pected area at room temperature, while heating in acidic med-
ium at 90 C for 1 h led to increased degradation up to 75% of
the expected area (Fig. 3A), Similarly, 1 N NaOH caused a
diminished degradation at room temperature; while heating
at 90 C for 1 h enhanced degradation (Fig. 3B) and only
70% of the expected area remained. Oxidative H2O2 degrada-
tion at room temperature revealed 93% from the peak area
compared to a standard of the same concentration. The situa-
tion changed upon heating at 80 C for 1 h (Fig. 3C), where the
remaining HCT peak eluted with 70% of the expected area.
Only one degradation peak can be detected for HCT eluting
at a retention time of 4.53 min in both hydrolytic and oxidative
degradation. The degradation peak shows an absorption spec-
trum similar to that of the intact drug. Under UV irradiationg the proposed HPLC method.
n (%) Retention times of degradation products (min)
3.18, 3.40, 4.03, 6.06, 8.87
4.34, 9.17
4.53
5.08, 6.04
–
4.53
6.02
7.49, 7.65, 7.85, 8.04
4.53
–
7.88, 9.22, 9.57
4.53, 6.69, 8.85
–
4.38
–
S1386 R.A. Shaalan et al.at 254 nm the HPLC chromatogram revealed degradation up
to 13% after being exposed to the UV light for 60 h, and the
degradation products appeared at 4.53, 6.69 and 8.85 minHCT 
Figure 3 HPLC chromatograms of 20 lg/ml solution of HCT aft
oxidative degradation, (D) photolytic degradation, and (E) thermal d(Fig. 3D). Finally, no signs of degradation of HCT could be
observed under dry heat conditions. HCT peak appeared at
its speciﬁc retention time (4.89 min) with area almost identicalB
C
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chromatograms did not show any extra peaks (Fig. 3E).
Similarly, the same stress conditions were applied to test the
stability indicating behavior of VAL. In strong acidic medium,
1 M HCl attacked VAL; a residual peak of the drug appeared
with less than 50% of the expected area, and degradation
products’ peaks eluted at about 4.34 and 9.17 min
(Fig. 4A).VAL appeared to be stable without any degradation
in strong basic medium (1 M NaOH at 90 C for 1 h) and the
chromatogram revealed an essentially intact VAL peak,
increasing the heating time to 2 h led to increased degradation
up to 13% only, and no degradation peaks appeared in the
chromatogram. Fig. 4B shows the chromatogram of VAL after
treatment with 1 M NaOH at 90 C for 2 h. HPLC after oxida-
tive H2O2 degradation at room temperature for 24 h revealed
an almost intact VAL peak with area about 96% of the intact
area. The situation was much different upon heating at 80 C
for 1 h, after which the remaining VAL peak had about 60%
of the expected area. Several degradation products’ peaks of
different intensities eluted at 7.49, 7.65, 7.85 and 8.04 min
(Fig. 4C). Photolytic degradation revealed almost intact
VAL peak with only 6% reduction in its peak area. Fig. 4D
shows the chromatogram of VAL after treatment at 254 nmfor 60 h where weak degradation peaks could be detected at
7.88, 9.22 and 9.57 min. Thermal degradation under the condi-
tions stated in Table 3 led to 5% degradation and the emer-
gence of a single degradation peak at 4.38 min. (Fig. 4E).
On the other hand, AML is well susceptible to hydrolysis;
acid hydrolysis with1 N HCl at room temperature for 24 h
caused about 15% reduction in the peak area of AML, while
1 N HCl with the aid of heating strongly attacked AML, an
approximately 30% decrease in the peak area was observed
after heating AML with 1 N HCl at 90 C for 10 min
(Fig. 5A). Well resolved minor degradation peaks can be de-
tected at retention times 3.18, 3.40, 4.03, 6.06 and 8.87 min.
Excessive heating for longer time or at higher temperatures
led to complete attack of the drug, and the chromatograms
showed almost no peak for AML. Similarly, sodium hydroxide
powerfully attacked AML. The drug readily decomposes in ba-
sic medium. Heating AML with 1 M NaOH at 60 C for only
10 min revealed the remaining AML peak which was about
65% of the expected area, in addition to the appearance of
degradation peaks at 5.08 and 6.04 min (Fig. 5B). Oxidative
degradation using H2O2 was performed at 80 C for 2 h where
the remaining AML peak was 75% and degradation peaks
eluted at 6.02 min (Fig. 5C).
VAL
VAL
VAL
A
B
C
Figure 4 HPLC chromatograms of 20 lg/ml solution of VAL after exposure to (A) acid degradation, (B) base degradation, (C) oxidative
degradation, (D) photolytic degradation, and (E) thermal dry heat degradation.
S1388 R.A. Shaalan et al.AML appeared to be stable without any degradation when
subjected to UV irradiation for 60 h, ﬁg. 5D shows the intact
drug with no degradation peaks. Almost the same condition
applied for the dry heat degradation where AML peak ap-peared at its speciﬁc retention time (6.42 min) with area almost
identical to that of the standard of the same concentration, fur-
thermore, the chromatograms did not show any extra peaks
(Fig. 5E).
VAL
VAL
D
E
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any of the three analytes and the nearest degradation products
peaks. Resolution was found not <2.23; this implies an ade-
quate baseline separation between the main drugs and any of
the degradation products. It is noteworthy to mention that
peak purity test results obtained from the diode-array detector
(DAD) conﬁrm that AML, VAL and HCT peaks are homog-
enous and pure in all the analyzed samples subjected to forced
degradation conditions.
3.3. Validation of the proposed method
3.3.1. Linearity and concentration ranges
The linearity of the proposed HPLC procedure was evalu-
ated by analyzing a series of different concentrations for
each of the three analytes. The linear regression equations
were generated by least squares treatment of the calibration
data. Under the optimized conditions described above, the
measured peak areas were found to be proportional to con-
centrations of the analytes. Table 4 presents the performance
data and statistical parameters including linear regression
equations, concentration ranges, correlation coefﬁcients,standard deviations of the intercept (Sa), slope (Sb) and
standard deviations of residuals (Sy/x). Regression analysis
shows good linearity as indicated from the correlation coef-
ﬁcient values (>0.9994). In addition, deviation around the
slope can be further evaluated by calculation of the
RSD% of the slope (Sb%) which were found to be less than
1.1%. The analysis of variance test for the regression lines
reveals that, for equal degrees of freedom, an increase in
the variance ratio (F values) means an increase in the mean
of squares due to regression and a decrease in the mean of
squares due to residuals. The greater the mean of squares
due to regression, the steeper is the regression line. The
smaller the mean of squares due to residuals, the less is
the scatter of experimental points around the regression line.
Consequently, regression lines with high F values (low signif-
icance F) are much better than those with lower ones. Good
regression lines show high values for both r and F statistical
parameters (Armitage and Berry, 1994).
3.3.2. Detection and quantiﬁcation limits
According to the pharmacopoeial recommendations (USP,
2011), the limit of detection is deﬁned as the concentration that
AB
c
Figure 5 HPLC chromatograms of 20 lg/ml solution of AML after exposure to (A) acid degradation, (B) base degradation, (C)
oxidative degradation, (D) photolytic degradation, and (E) thermal dry heat degradation.
S1390 R.A. Shaalan et al.has a signal-to-noise ratio of 3:1, while for limit of quantiﬁca-
tion, the ratio considered is 10:1. The LOD and LOQ valuesfor the three antihypertensives were calculated and presented
in Table 4.
DE
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Table 4 Analytical parameters for the determination of AML-VAL-HCT mixture using the proposed HPLC-DAD method.
Parameter AML VAL HCT
Wavelength (nm) 238 225 225
Concentration range (lg/mL) 5–200 5–200 10–200
Intercept (a) 137.47 134.36 44.41
Sa
a 25.14 74.15 55.66
Slope (b) 51.26 72.38 117.05
Sb
b 0.56 0.73 1.78
RSD% of the slope (Sb%) 1.08 1.01 1.52
Correlation coeﬃcient (r) 0.99935 0.99959 0.99967
Sy/x
c 65.70 172.87 88.98
Fd 8497.32 9792.09 9537.13
Signiﬁcance F 3.06 · 1017 1.21 · 1013 2.13 · 109
LODe (lg/mL) 0.26 0.24 0.12
LOQf (lg/mL) 0.85 0.80 0.40
a Standard deviation of the intercept.
b Standard deviation of the slope.
c Standard deviation of residuals.
d Variance ratio, equals the mean of squares due to regression divided by the mean of squares about regression (due to residuals).
e Limit of detection.
f Limit of quantiﬁcation.
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Table 5 Precision and accuracy for the determination of AML, VAL and HCT in bulk form using the proposed HPLC-DAD
method.
Analyte Nominal value (lg/mL) Within-day Between-day
Found ± SDa (lg/mL) RSD(%)b Er(%)
c Found ± SDa (lg/mL) RSD(%)b Er(%)
c
AML 10 9.99 ± 0.07 0.7 0.10 10.06 ± 0.08 0.78 0.01
20 19.99 ± 0.30 1.52 0.05 19.78 ± 0.11 0.55 1.10
150 149.85 ± 0.22 0.15 0.10 149.73 ± 0.81 0.54 0.18
VAL 20 20.11 ± 0.15 0.74 0.54 19.69 ± 0.17 0.85 1.55
80 79.95 ± 0.50 0.62 0.05 80.96 ± 0.88 1.09 1.18
200 199.50 ± 0.20 0.10 0.004 200.02 ± 1.07 0.54 0.01
HCT 25 25.08 ± 0.22 0.87 0.32 25.02 ± 0.36 1.46 0.08
100 99.83 ± 0.60 0.60 0.17 100.61 ± 0.68 0.68 0.61
150 152.24 ± 1.13 0.75 0.15 152.79 ± 0.63 0.41 1.86
a Mean ± standard deviation for three determinations.
b % Relative standard deviation.
c % Relative error.
S1392 R.A. Shaalan et al.3.3.3. Precision and accuracy
The within-day (intra-day) precision and accuracy for the pro-
posed method were studied at three concentration levels for
each compound using three replicate determinations for each
concentration within one day. Similarly, the between-day (in-
ter-day) precision and accuracy were tested by analyzing the
same three concentrations for each compound using three rep-
licate determinations repeated on three days. Recoveries were
calculated using the corresponding regression equations and
they were satisfactory. The percentage relative standard devia-
tion (RSD%) and percentage relative error (Er%) did not ex-
ceed 1.6% proving the high repeatability and accuracy of the
developed method for the estimation of the analytes in their
bulk form (Table 5).
3.3.4. Selectivity and speciﬁcity
Method selectivity was examined by preparing several labora-
tory-prepared mixtures of the three compounds at various con-
centrations within the linearity ranges mentioned in Table 4.
The laboratory-prepared mixtures were analyzed according
to the previously described procedure. The analysis results
including percentage relative standard deviation (RSD%)
and the percentage relative error (Er%) values shown in Table 6
were satisfactory thus validating selectivity, precision and
accuracy of the developed method and demonstrating its capa-
bility to resolve and quantify the analytes in different ratios.
Speciﬁcity is deﬁned as the ability to access unequivocally
the analyte in the presence of components that may be ex-
pected to be present, such as impurities, degradation productsTable 6 Determination of AML-VAL-HCT laboratory-prepared m
Nominal value (lg/mL) Found ± SDa (lg/mL)
AML VAL HCT AML VAL H
100 100 100 100.02 ± 0.88 100.37 ± 0.52 10
25 25 150 25.12 ± 0.12 25.13 ± 0.13 14
25 150 25 24.91 ± 0.12 150.35 ± 0.49 2
150 25 25 150.20 ± 0.26 25.19 ± 0.23 2
25 160 25 24.99 ± 0.10 159.67 ± 0.42 2
a Mean ± standard deviation for ﬁve determinations.
b % Relative standard deviation.
c % Relative error.and matrix components (USP, 2011), and this is well demon-
strated in detail through the analysis of pharmaceutical dosage
form and forced degradation studies. No extra peaks were ob-
served from any of the inactive ingredients in the dosage form.
Also, the DAD enables peak purity veriﬁcation, where no signs
of co-elution from any of the inactive components were de-
tected. Selectivity was demonstrated by separation of the three
analytes from their relevant degradation products under differ-
ent stress conditions.
3.3.5. Robustness
Robustness was examined by evaluating the inﬂuence of small
variations in different conditions such as concentration of
phosphoric acid solution (±0.025 M), source of acetonitrile
(Scharlau Chemie S.A., Spain or SDS, France or Labscan, Po-
land), working wavelength (±2 nm), ﬂow rate (±0.1 mL/min)
and column temperature (±2 C). These variations did not
have any signiﬁcant effect on the measured responses or the
chromatographic resolution. RSD% for the measured peak
areas using these variations did not exceed 3%.
3.4. Stability of solutions
The stability of standard working solutions as well as sample
solutions in distilled water was examined and no chromato-
graphic changes were observed within 24 h at room tempera-
ture. Also, the stock solutions prepared in HPLC-grade
methanol were stable for at least 2 weeks when stored refriger-
ated at 4 C. Retention times and peak areas of the drugsixtures using the proposed HPLC-DAD method.
RSD(%)b Er(%)
c
CT AML VAL HCT AML VAL HCT
0.30 ± 0.33 0.88 0.51 0.33 0.02 0.37 0.30
9.87 ± 0.57 0.46 0.53 0.38 0.48 0.52 0.09
5.07 ± 0.08 0.49 0.33 0.32 0.36 0.23 0.28
4.91 ± 0.05 0.18 0.89 0.18 0.13 0.76 0.36
5.01 ± 0.28 0.38 0.26 1.13 0.04 0.21 0.04
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Validated stability-indicating HPLC-DAD method of analysis for the antihypertensive triple mixture S1393remained unchanged and no signiﬁcant degradation was ob-
served during these periods.
3.5. Analysis of pharmaceutical dosage form
The optimized HPLC-DAD procedure was applied for the as-
say of this drug combination in the pharmaceutical formula-
tion (Exforge HCT tablets). The active ingredients were
extracted with the same solvent used for the preparation of
the standard stock solutions (HPLC-grade methanol) then
dilution was made with distilled water to reach concentration
levels within the speciﬁed ranges. The active ingredients eluted
at their speciﬁc retention times. No interfering peaks were ob-
served from any of the inactive ingredients or the colored coat
of the analyzed tablets. The diode-array detection enables peak
purity veriﬁcation where no signs of co-elution from any of the
inactive adjuvants were detected. Recoveries were calculated
using both external standard and standard addition methods.
The assay results revealed satisfactory accuracy and precision
as indicated from% recovery, SD and RSD% values (Table 7).
Furthermore, a reference RP-HPLC method (Shaalan and Be-
lal, 2012) was applied for the estimation of the analytes in their
combined formulation. Recovery data obtained from the
developed HPLC method were statistically compared with
those of the reference method using Student’s t- and the vari-
ance ratio F-tests. In both tests, the calculated values did not
exceed the theoretical ones at the 95% conﬁdence level which
indicated that there were no signiﬁcant differences between the
recoveries obtained from the developed method and those of
the reference method (Table 7). It is evident from these results
that the proposed method is applicable to the assay of this
drug combination with a satisfactory level of selectivity, accu-
racy and precision.
4. Conclusions
In this study, a simple, speciﬁc and reliable gradient elution
HPLC-DAD procedure was developed for the assay of amlo-
dipine besylate (AML), valsartan (VAL) and hydrochlorothia-
zide in their pharmaceutical combination. The three analytes
were subjected to forced degradation using several stress
(hydrolytic, oxidative, photolytic and thermal) conditions,
and the proposed method was successfully employed for the
resolution of the analytes’ peaks from those of the forced deg-
radation products. The most important feature in the pro-
posed method is the speciﬁcity and stability-indicating
merits. To our present knowledge, no such speciﬁc and stabil-
ity indicating procedure has been reported for the assay of this
ternary drug mixture. The developed method made use of
DAD as a tool for peak identity and purity conﬁrmation; how-
ever, it can be adapted to conventional HPLC with UV detec-
tion which is the most popular in quality control laboratories.
Finally, the method was thoroughly validated, therefore, it can
be recommended for routine analysis and for checking quality
during stability studies of the cited drugs.
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